High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition. The profit came in below the consensus estimate of 5 cents a share.
Biogen’s second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.
BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price.
Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern. The company presented the update dur
The mid-stage study missed its primary goal, and the drug's lowest dose outperformed higher doses in ways the company cannot yet explain
Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell nearly 9% following the Phase 2 CELIA readout of its highly anticipated Alzheimer’s therapy, diranersen. While the drug achieved a major scientific milestone by robustly clearing tau pathology, an unexpected inverse dose response—where the lowest dose performed the best—left Wall Street analysts confused and triggered a sell-off. Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cogniti
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.
BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA study failed to meet its endpoints. Legal investigations have been launched into Biogen following missed endpoints in the Phase 2 CELIA study for Alzheimer's therapy diranersen. These developments affect Biogen's pipeline in neurodegenerative diseases and add legal and regulatory scrutiny around its R&D disclosures. For investors following NasdaqGS:BIIB, the halt of BIIB122...
Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock
The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
